These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12643016)

  • 21. Another confirmation of the inactivity of topotecan in ovarian cancer.
    McGuire WP
    J Natl Cancer Inst; 2010 Oct; 102(20):1523-4. PubMed ID: 20937989
    [No Abstract]   [Full Text] [Related]  

  • 22. Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials.
    Zhang H; Jia L; Xu Y; Zhou XC; Kong B; Li D
    J Chemother; 2012 Apr; 24(2):67-73. PubMed ID: 22546760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    Atkins CD
    J Natl Cancer Inst; 2000 Sep; 92(17):1446-7. PubMed ID: 10974091
    [No Abstract]   [Full Text] [Related]  

  • 24. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.
    Muntz HG; Malpass TW; McGonigle KF; Robertson MD; Weiden PL
    Cancer; 2008 Aug; 113(3):490-6. PubMed ID: 18521923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.
    Stuart GC
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S8-15. PubMed ID: 13129490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
    Lorusso D; Mainenti S; Ferrandina G; Scambia G
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):987-91. PubMed ID: 20645686
    [No Abstract]   [Full Text] [Related]  

  • 29. Salvage therapy for ovarian cancer.
    Garcia AA
    Curr Oncol Rep; 1999 Sep; 1(1):64-70. PubMed ID: 11122800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
    J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
    [No Abstract]   [Full Text] [Related]  

  • 31. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.
    Alberts DS; Markman M; Muggia F; Ozols RF; Eldermire E; Bookman MA; Chen T; Curtin J; Hess LM; Liebes L; Young RC; Trimble E
    Gynecol Oncol; 2006 Dec; 103(3):783-92. PubMed ID: 17070570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].
    du Bois A; Lück HJ; Pfisterer J; Meier W; Bauknecht T
    Zentralbl Gynakol; 2000; 122(5):255-67. PubMed ID: 10857212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
    Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
    Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
    Morgan RJ; Doroshow JH; Leong L; Schriber J; Shibata S; Forman S; Hamasaki V; Margolin K; Somlo G; Alvarnas J; McNamara M; Longmate J; Raschko J; Chow W; Vasilev S; McGonigle K; Yen Y
    Bone Marrow Transplant; 2001 Nov; 28(9):859-63. PubMed ID: 11781646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
    Michener CM; Belinson JL
    Oncology (Williston Park); 2005 Sep; 19(10):1277-85; discussion 1285, 1288, 1293. PubMed ID: 16285224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
    Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A
    Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
    [No Abstract]   [Full Text] [Related]  

  • 39. Common epithelial cancer of the ovary (2).
    Richardson GS; Scully RE; Nikrui N; Nelson JH
    N Engl J Med; 1985 Feb; 312(8):474-83. PubMed ID: 3881673
    [No Abstract]   [Full Text] [Related]  

  • 40. Intraperitoneal chemotherapy in the treatment of ovarian cancer.
    Markman M
    Ann Med; 1996 Aug; 28(4):293-6. PubMed ID: 8862681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.